{"id":55027,"date":"2026-01-22T01:31:34","date_gmt":"2026-01-21T17:31:34","guid":{"rendered":"https:\/\/flcube.com\/?p=55027"},"modified":"2026-01-22T01:31:35","modified_gmt":"2026-01-21T17:31:35","slug":"astrazeneca-to-delist-from-nasdaq-shift-direct-nyse-listing-in-share-structure-unification","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55027","title":{"rendered":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification"},"content":{"rendered":"\n<p><strong>AstraZeneca plc<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ:\u202fAZN<\/a>) announced it will <strong>delist its American Depositary Shares (ADS) and debt securities from Nasdaq<\/strong> and complete a <strong>direct listing of its ordinary shares on the New York Stock Exchange<\/strong>, effective <strong>after market close on 30\u202fJan\u202f2026<\/strong>. Ordinary shares and debt will commence trading on NYSE on <strong>2\u202fFeb\u202f2026<\/strong>, maintaining the <strong>&#8220;AZN&#8221; ticker symbol<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AstraZeneca plc (NASDAQ:\u202fAZN)<\/td><\/tr><tr><td><strong>Current Listing<\/strong><\/td><td>Nasdaq (ADSs and debt securities)<\/td><\/tr><tr><td><strong>New Listing<\/strong><\/td><td>New York Stock Exchange (ordinary shares and debt)<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>After market close, 30\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>NYSE Trading Start<\/strong><\/td><td>2\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Ticker Symbol<\/strong><\/td><td><strong>AZN<\/strong> (unchanged)<\/td><\/tr><tr><td><strong>Share Structure Shift<\/strong><\/td><td>From ADSs (2\u2011for\u20111 basis) to direct listing of <strong>$0.25 ordinary shares<\/strong><\/td><\/tr><tr><td><strong>Rationale<\/strong><\/td><td>Unify share listing structure across LSE, Nasdaq Stockholm, and NYSE<\/td><\/tr><tr><td><strong>Shareholder Approval<\/strong><\/td><td>Approved plan<\/td><\/tr><tr><td><strong>ADRs<\/strong><\/td><td>ADSs will be exchangeable for ordinary shares on 1\u2011for\u20112 basis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplified Structure:<\/strong> Eliminates ADS layer, reducing administrative complexity and <strong>depositary fees<\/strong> estimated at <strong>$8\u201112\u202fmillion annually<\/strong><\/li>\n\n\n\n<li><strong>Global Harmonization:<\/strong> Aligns trading structure with UK home market governance and Swedish listing<\/li>\n\n\n\n<li><strong>Investor Access:<\/strong> Direct ordinary share trading on NYSE provides <strong>global institutional investors<\/strong> with clearer exposure and <strong>eliminates ADS conversion friction<\/strong><\/li>\n\n\n\n<li><strong>Liquidity:<\/strong> Expected to <strong>increase trading volume<\/strong> in ordinary shares, improving price discovery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-shareholder-considerations\">Market Impact &amp; Shareholder Considerations<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Current (ADS)<\/th><th>New (Ordinary)<\/th><\/tr><\/thead><tbody><tr><td><strong>Trading Venues<\/strong><\/td><td>Nasdaq (US) only<\/td><td>NYSE (US) + LSE (UK) + Nasdaq Stockholm (SE)<\/td><\/tr><tr><td><strong>Settlement<\/strong><\/td><td>DTC (US)<\/td><td>DTC (US) + CREST (UK) + Euroclear (SE)<\/td><\/tr><tr><td><strong>Voting Rights<\/strong><\/td><td>Indirect via ADS depositary<\/td><td>Direct shareholder voting<\/td><\/tr><tr><td><strong>Dividend Treatment<\/strong><\/td><td>USD, net of depositary fees<\/td><td>USD\/GBP\/SEK, no depositary fees<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US Shareholders:<\/strong> ADS holders will <strong>receive ordinary shares<\/strong> (or cash equivalent) through a <strong>voluntary exchange program<\/strong> by <strong>Q2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Index Implications:<\/strong> FTSE 100 and OMX Stockholm constituents unchanged; S&amp;P 500 eligibility remains (primary listing NYSE)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Savings:<\/strong> <strong>$8\u201112\u202fmillion annual ADS depositary fee elimination<\/strong><\/li>\n\n\n\n<li><strong>One\u2011Time Costs:<\/strong> Estimated <strong>$15\u202fmillion<\/strong> for legal, regulatory, and IT systems integration<\/li>\n\n\n\n<li><strong>EPS Impact:<\/strong> <strong>Neutral to slightly accretive<\/strong> by 2027 due to fee savings<\/li>\n\n\n\n<li><strong>Free Float:<\/strong> No change; all listings represent same underlying share capital<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding listing transition timelines, cost savings, and trading liquidity. Actual results may differ due to regulatory approvals, shareholder exchange participation rates, and market volatility during transition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,871],"class_list":["post-55027","post","type-post","status-publish","format-standard","hentry","category-company","tag-astrazeneca","tag-az","tag-nasdaq-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the &quot;AZN&quot; ticker symbol.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55027\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the &quot;AZN&quot; ticker symbol.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55027\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-21T17:31:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-21T17:31:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification\",\"datePublished\":\"2026-01-21T17:31:34+00:00\",\"dateModified\":\"2026-01-21T17:31:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027\"},\"wordCount\":380,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55027#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55027\",\"name\":\"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-21T17:31:34+00:00\",\"dateModified\":\"2026-01-21T17:31:35+00:00\",\"description\":\"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the \\\"AZN\\\" ticker symbol.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55027\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55027#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the \"AZN\" ticker symbol.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55027","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification","og_description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the \"AZN\" ticker symbol.","og_url":"https:\/\/flcube.com\/?p=55027","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-21T17:31:34+00:00","article_modified_time":"2026-01-21T17:31:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55027#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55027"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification","datePublished":"2026-01-21T17:31:34+00:00","dateModified":"2026-01-21T17:31:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55027"},"wordCount":380,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55027#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55027","url":"https:\/\/flcube.com\/?p=55027","name":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-21T17:31:34+00:00","dateModified":"2026-01-21T17:31:35+00:00","description":"AstraZeneca plc (AZ, NASDAQ:\u202fAZN) announced it will delist its American Depositary Shares (ADS) and debt securities from Nasdaq and complete a direct listing of its ordinary shares on the New York Stock Exchange, effective after market close on 30\u202fJan\u202f2026. Ordinary shares and debt will commence trading on NYSE on 2\u202fFeb\u202f2026, maintaining the \"AZN\" ticker symbol.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55027#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55027"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55027#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca to Delist from Nasdaq, Shift Direct NYSE Listing in Share Structure Unification"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55027"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55027\/revisions"}],"predecessor-version":[{"id":55028,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55027\/revisions\/55028"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}